Top Markets
Coin of the day
Golden Biotechnology Corporation Golden Biotechnology Corporation

Golden Biotechnology Corporation

4132
Rangering i aksjer #29686
Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City,... Golden Biotechnology Corporation, founded in 2002 and based in New Taipei City, Taiwan, is engaged in both pharmaceutical drug discovery and the production of health-enhancing dietary supplements. The company operates internationally, serving markets in Taiwan, the United States, Japan, China, Korea, and Singapore. Its varied product line includes several health supplements: Liverty, formulated to support liver function and help alleviate fatigue. Rasle, which serves as an adjunctive therapy for autoimmune conditions. ZSAINO, a nutritional product designed to aid recovery from illness and boost general well-being. UMOOZE, a specialized herbal blend targeting optimal health for men. Furthermore, Golden Biotechnology is developing Antroquinonol, an anticancer molecule. This compound is currently utilized in the treatment of severe conditions such as pancreatic cancer, acute myeloid leukemia, and hepatocellular carcinoma, in addition to addressing hypercholesterolemia and hyperlipidemia.
Aksjekurs
$0.11034263
Sist synkronisert: 2026-04-09
Markedsverdi
$20.11M
Endring (1 dag)
-31.83%
Endring (1 år)
-73.09%
Land
TW
Handel Golden Biotechnology Corporation (4132)

Kategori

Inntekter for Golden Biotechnology Corporation (4132)
Inntekter i 2026 TTM: 0
Ifølge Golden Biotechnology Corporation sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Golden Biotechnology Corporation fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter